Rebranded Servier eyes €3bn in cancer drug sales by 2030
pharmaphorum
OCTOBER 6, 2022
The strategy to build in cancer dates back to 2015, and has since gathered momentum with the purchase of the oncology businesses of Shire and Agios Pharma in 2018 and 2020, for $2.4 billion and $1.8 billion respectively, as well as smaller deals such as its takeover of Danish antibody specialist Symphogen.
Let's personalize your content